Wins the First Series of Investment, mClinica Directly Aims at the Indonesian Market

One of the startups from Singapore, mClinica recently received investment funding led by three global investment companies namely 500Startups, IMJ Investment Partners, and Kickstart Ventures. In this first series of funding, the amount of which is not stated, mClinica is reportedly directly targeting the Indonesian market as one of its efforts to strengthen its business base in the Southeast Asia region.

For those who don't know, mClinica is a startup that provides technology solutions for the healthcare world. The mClinica platform itself was developed as a mode of liaison between many pharmaceutical companies with pharmacies and patients via only a mobile device.

The startup, which was founded in 2012, has a number of integrated products, such as several mobile applications that can be used by both patients and pharmacists, to a cloud-based platform solution product called mClinica 360, which is specifically intended for pharmaceutical companies, distributors, and pharmacies. in accessing market analysis data for business support purposes.

As reported by the site e27 today (23/10), apart from targeting the Indonesian market, a number of other developing countries in the Southeast Asia region are also targeted by looking at the huge market potential. Unmitigated, other countries such as Vietnam and Thailand will also be tested in the near future, apart from the investment funds obtained, mClinica will also continue to improve its business performance in an effort to reach a mobile user base of more than 550 million in 25 countries in the region. Asia and Africa.

Minette Navarrete, as President of Kickstart, said that his investment in mClinica was triggered by the mClinica concept which he saw as a platform with the right solution for the healthcare industry, which of course has great business potential.

“mClinica enhances retail sales services for patients and retail customers, drugstores, and major pharmaceutical companies. By combining software sophistication with in-depth analysis of patient needs, pharmaceutical industry, and retail experiences in emerging markets, mClinica creates value for the ecosystem, and the traction it gains demonstrates that."

In line with this, Koichi Saito, Director of IMJ Investment Partners also said, mClinica managed to attract his attention after the startup was able to develop a business model that he saw as quite unique and potentially bright.

"mClinica is the most attractive mobile-based healthcare startup for us. This is evidenced by its impressive growth rate based on two very unique business models. The better mClinica's performance as a business unit, the better its service to patients," said Koichi.

mClinica's own business performance is currently considered to have progressed very rapidly. Currently, mClinica is claimed to have established partnerships with more than 14.000 pharmaceutical companies in 20 countries with market coverage. Even in the Philippines, one of two independent pharmaceutical companies there has become part of mClinica, this is what ultimately makes mClinica the largest healthcare industry-based startup in the country. What about its potential in Indonesia?

So far, there is no platform similar to mClinica that can be a competitor in Indonesia, by entering a market that is still lacking competitors, it is not impossible that mClinica will have bright opportunities, besides the pharmaceutical industry in Indonesia is also running quite stable.

[photo illustration: Shutterstock]